CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
Ishani Wickramage,1 Kamani Hemamala Tennekoon,1 Merenchi Arachchige Yasantha Ariyaratne,2 Asanka Sudeshini Hewage,1 Tharmini Sundralingam,1 1Institute of Biochemistry, Molecular Biology and Biotechnology (IBMBB), University of Colombo, Colombo, Sri Lanka; 2National Cancer Institute, Maharagama, Sri...
Main Authors: | Wickramage I, Tennekoon KH, Ariyaratne MAY, Hewage AS, Sundralingam T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-03-01
|
Series: | Breast Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/cyp2d6-polymorphisms-may-predict-occurrence-of-adverse-effects-to-tamo-peer-reviewed-article-BCTT |
Similar Items
-
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
by: Charoenchokthavee W, et al.
Published: (2017-04-01) -
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by: Roberta Ferraldeschi, et al.
Published: (2010-04-01) -
Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
by: Amira Boucenna, et al.
Published: (2022-08-01) -
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
by: Jennifer D. Brooks, et al.
Published: (2018-12-01) -
Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
by: Zahra Khalaj, et al.
Published: (2019-05-01)